ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Active Not Recruiting • Phase II • Rheumatology • NCT04895696.
- Trial testing whether a new drug called Afimetoran works better than placebo for treating active lupus.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran. Conditions: Systemic Lupus Erythematosus Interventions: Afimetoran, Placebo Lead Sponsor: Beeline Medicines Corporation Planned Enrollment: 248 participants